Home The Word Brain My Amedeo FAQ Privacy About   


As of October 2023, Amedeo had
12,263 active subscribers


  Chronic Heart Failure

  Free Subscription


Articles published in Am Heart J

Retrieve available abstracts of 121 articles:
HTML format



Single Articles


    November 2023
  1. SAVARESE G, Gatti P, Benson L, Adamo M, et al
    LEFT VENTRICULAR EJECTION FRACTION DIGIT BIAS AND RECLASSIFICATION OF HEART FAILURE WITH MILDLY REDUCED VS. REDUCED EJECTION FRACTION BASED ON THE 2021 DEFINITION AND CLASSIFICATION OF HEART FAILURE: Abbreviated title: DIGIT BIAS AND HEART FAILURE REC
    Am Heart J. 2023 Nov 14:S0002-8703(23)00317-4. doi: 10.1016/j.ahj.2023.
    PubMed     Abstract available


  2. SALAHUDDIN T, Hebbe A, Daus M, Essien UR, et al
    Trends and Site-level Variation of Novel Cardiovascular Medication Utilization among Patients Admitted for Heart Failure or Coronary Artery Disease in the US Veterans Affairs System: 2017-2021.
    Am Heart J. 2023 Nov 11:S0002-8703(23)00318-6. doi: 10.1016/j.ahj.2023.
    PubMed     Abstract available


    October 2023
  3. EGBE AC, Miranda WR, Jain CC, Stephens EH, et al
    Temporal Changes in Clinical Characteristics and Outcomes of Adults With Congenital Heart Disease.
    Am Heart J. 2023;264:1-9.
    PubMed     Abstract available


    September 2023
  4. FLETT A, Cebula A, Nicholas Z, Adam R, et al
    Rationale and study protocol for the BRITISH randomised trial (Using cardiovascular magnetic resonance identified scar as the Benchmark Risk Indication Tool for Implantable cardioverter defibrillators in patients with Non-Ischaemic Cardiomyopathy and
    Am Heart J. 2023 Sep 28:S0002-8703(23)00281-8. doi: 10.1016/j.ahj.2023.
    PubMed     Abstract available


    August 2023
  5. JAMES S, Erlinge D, Storey RF, McGuire DK, et al
    Rationale and design of the DAPA-MI trial: Dapagliflozin in patients without diabetes mellitus with acute myocardial infarction.
    Am Heart J. 2023 Aug 25:S0002-8703(23)00207-7. doi: 10.1016/j.ahj.2023.
    PubMed     Abstract available


  6. HARRINGTON J, Mentz RJ, Rockhold FW, Garg J, et al
    Baseline Characteristics of Patients in the Randomized Study to Investigate the Efficacy and Safety of Ferric Carboxymaltose as Treatment for Heart Failure with Iron Deficiency: HEART-FID Trial.
    Am Heart J. 2023 Aug 18:S0002-8703(23)00202-8. doi: 10.1016/j.ahj.2023.
    PubMed     Abstract available


  7. COX ZL, Siddiqi HK, Stevenson LW, Bales B, et al
    Randomized controlled trial of urinE chemiStry guided aCute heArt faiLure treATmEnt (ESCALATE): Rationale and design.
    Am Heart J. 2023 Aug 4:S0002-8703(23)00187-4. doi: 10.1016/j.ahj.2023.
    PubMed     Abstract available


    July 2023
  8. VINEREANU D, Wojdyla DM, Alexander JH, Lopes RD, et al
    Heart Rate and Death and Hospitalization for Heart Failure in Patients with Persistent or Permanent Atrial Fibrillation: Insights from the ARISTOTLE Trial.
    Am Heart J. 2023 Jul 26:S0002-8703(23)00179-5. doi: 10.1016/j.ahj.2023.
    PubMed     Abstract available


  9. MATASIC DS, Blumenthal RS, Fonarow GC, Gulati M, et al
    Taking the next step in cardiovascular risk reduction: Integrating heart failure and peripheral arterial disease prevention.
    Am Heart J. 2023 Jul 20:S0002-8703(23)00176-X. doi: 10.1016/j.ahj.2023.
    PubMed    


  10. BANKE A, Andersson C, D'Souza M, Fosbol E, et al
    Importance of familial predisposition to heart failure to the risk of anthracycline related cardiotoxicity: A nationwide study.
    Am Heart J. 2023 Jul 13:S0002-8703(23)00175-8. doi: 10.1016/j.ahj.2023.
    PubMed     Abstract available


  11. JEFFERIES JL, Kovesdy CP, Ronco C
    Contemporary laboratory assessment of acute cardiorenal syndrome for early diagnosis: A call for action.
    Am Heart J. 2023;261:75-84.
    PubMed     Abstract available


  12. PETERS AE, Solomon N, Chiswell K, Fonarow GC, et al
    Transthyretin Amyloid Cardiomyopathy Among Patients Hospitalized for Heart Failure and Performance of an Adapted Wild-Type ATTR-CM Machine Learning Model: Findings from GWTG-HF.
    Am Heart J. 2023 Jul 1:S0002-8703(23)00169-2. doi: 10.1016/j.ahj.2023.
    PubMed     Abstract available


    June 2023
  13. GANGAVELLI A, Liu Z, Wang J, Okoh A, et al
    Racial Differences in Low Natriuretic Peptide Levels: Implications for Heart Failure Clinical Trials.
    Am Heart J. 2023 Jun 19:S0002-8703(23)00163-1. doi: 10.1016/j.ahj.2023.
    PubMed     Abstract available


  14. VIOLI F, Castellani V, Menichelli D, Pignatelli P, et al
    GUT BARRIER DYSFUNCTION AND ENDOTOXEMIA IN HEART FAILURE: A DANGEROUS CONNUBIUM?
    Am Heart J. 2023 Jun 8:S0002-8703(23)00146-1. doi: 10.1016/j.ahj.2023.
    PubMed     Abstract available


  15. MEWTON N, Donal E, Picard F, Derimay F, et al
    Prognostic impact of precipitated cardiac decompensation in symptomatic heart failure with reduced ejection fraction and severe secondary mitral regurgitation.
    Am Heart J. 2023 Jun 2:S0002-8703(23)00137-0. doi: 10.1016/j.ahj.2023.
    PubMed     Abstract available


    May 2023
  16. KRONBORG MB, Frausing MHJP, Svendsen JH, Johansen JB, et al
    Does Targeted Positioning of the Left Ventricular Pacing Lead Towards the Latest Local Electrical Activation in Cardiac Resynchronization Therapy Reduce the Incidence of Death or Hospitalization for Heart Failure?
    Am Heart J. 2023 May 21:S0002-8703(23)00129-1. doi: 10.1016/j.ahj.2023.
    PubMed     Abstract available


  17. ARNOLD SV, Gosch K, Kosiborod M, Wong ND, et al
    Contemporary Use of Cardiovascular Risk Reduction Strategies in Type 2 Diabetes. Insights from The Diabetes Collaborative Registry.
    Am Heart J. 2023 May 8:S0002-8703(23)00112-6. doi: 10.1016/j.ahj.2023.
    PubMed     Abstract available


  18. CHOUAIRI F, Pinsker B, Miller PE, Fudim M, et al
    Effects of COVID-19 on Heart Failure Admissions.
    Am Heart J. 2023 May 6:S0002-8703(23)00111-4. doi: 10.1016/j.ahj.2023.
    PubMed     Abstract available


  19. SELAMET TIERNEY ES, Palaniappan L, Leonard M, Long J, et al
    Design and rationale of re-energize fontan: Randomized exercise intervention designed to maximize fitness in fontan patients.
    Am Heart J. 2023;259:68-78.
    PubMed     Abstract available


    April 2023
  20. RAO VN, Cyr D, Wruck L, Sanders G, et al
    Electronic Health Record Characterization and Outcomes of Heart Failure with Preserved Ejection Fraction.
    Am Heart J. 2023 Apr 26:S0002-8703(23)00100-X. doi: 10.1016/j.ahj.2023.
    PubMed     Abstract available


  21. FU G, Zhou Z, Jian B, Huang S, et al
    Systolic blood pressure time in target range and long-term outcomes in patients with ischemic cardiomyopathy.
    Am Heart J. 2023;258:177-185.
    PubMed     Abstract available


  22. JOHNSON M, Morrison FJ, McMahon G, Su M, et al
    Outcomes in patients with cardiometabolic disease who develop hyperkalemia while treated with a renin-angiotensin-aldosterone system inhibitor.
    Am Heart J. 2023;258:49-59.
    PubMed     Abstract available


  23. MUKHOPADHYAY A, Reynolds HR, Xia Y, Phillips LM, et al
    Design and pilot implementation for the BETTER CARE-HF trial: A pragmatic cluster-randomized controlled trial comparing two targeted approaches to ambulatory clinical decision support for cardiologists.
    Am Heart J. 2023;258:38-48.
    PubMed     Abstract available


    March 2023
  24. OMEROVIC E, James S, Erlinge D, Hagstrom H, et al
    Rationale and design of BROKEN-SWEDEHEART: a registry-based, randomized, parallel, open-label multicenter trial to test pharmacological treatments for broken heart (takotsubo) syndrome.
    Am Heart J. 2023;257:33-40.
    PubMed     Abstract available


    February 2023
  25. UPSHAW JN, Parker S, Gregory D, Koethe B, et al
    The effect of tablet computer-based telemonitoring added to an established telephone disease management program on heart failure hospitalizations: The Specialized Primary and Networked Care in Heart Failure (SPAN-CHF) III Randomized Controlled Trial.
    Am Heart J. 2023 Feb 24:S0002-8703(23)00042-X. doi: 10.1016/j.ahj.2023.
    PubMed     Abstract available


  26. YAKU H, Kato T, Morimoto T, Kaneda K, et al
    Rationale and Study design of the GOREISAN for Heart Failure (GOREISAN-HF) trial: A randomized clinical trial.
    Am Heart J. 2023 Feb 23:S0002-8703(23)00045-5. doi: 10.1016/j.ahj.2023.
    PubMed     Abstract available


  27. FAXEN J, Benson L, Mantel A, Savarese G, et al
    Association Between Rheumatoid Arthritis and Incident Heart Failure by Left Ventricular Ejection Fraction.
    Am Heart J. 2023 Feb 9:S0002-8703(23)00035-2. doi: 10.1016/j.ahj.2023.
    PubMed     Abstract available


    January 2023
  28. SILVAIN J, Cayla G, Ferrari E, Range G, et al
    betaeta Blocker Interruption after Uncomplicated Myocardial Infarction: Rationale and Design of the randomized ABYSS trial.
    Am Heart J. 2023 Jan 19:S0002-8703(23)00021-2. doi: 10.1016/j.ahj.2023.
    PubMed     Abstract available


    December 2022
  29. TANG X, Lingzhu Y, Xing Z
    Predicted lean body mass, fat mass, and heart failure in patients with type 2 diabetes mellitus.
    Am Heart J. 2022 Dec 14:S0002-8703(22)00328-3. doi: 10.1016/j.ahj.2022.
    PubMed     Abstract available


  30. HORIUCHI Y, Matsue Y, Nogi K, Onitsuka K, et al
    Early treatment with a sodium-glucose co-transporter 2 inhibitor in high-risk patients with acute heart failure: rationale for and design of the EMPA-AHF trial.
    Am Heart J. 2022 Dec 8:S0002-8703(22)00325-8. doi: 10.1016/j.ahj.2022.
    PubMed     Abstract available


  31. GHAZI L, O'Connor K, Yamamoto Y, Fuery M, et al
    Pragmatic Trial of Messaging to Providers About Treatment of Acute Heart Failure: The PROMPT-AHF Trial.
    Am Heart J. 2022 Dec 6:S0002-8703(22)00323-4. doi: 10.1016/j.ahj.2022.
    PubMed     Abstract available


  32. LIU J, Wang B, Li Y, Yan X, et al
    Rationale and design of the Effects of intensive Systolic blood Pressure lowering treatment in reducing RIsk of vascular evenTs (ESPRIT): a multicenter open-label randomized controlled trial.
    Am Heart J. 2022 Dec 6:S0002-8703(22)00322-2. doi: 10.1016/j.ahj.2022.
    PubMed     Abstract available


    November 2022
  33. NELSON MB, Shiroma EJ, Kitzman DW, Duncan PW, et al
    Physical Activity and Relationship to Physical Function, Quality of Life, and Cognitive Function in Older Patients with Acute Decompensated Heart Failure.
    Am Heart J. 2022 Nov 10. pii: S0002-8703(22)00283.
    PubMed     Abstract available


  34. JANUZZI JL JR, Butler J, Prato SD, Ezekowitz JA, et al
    Rationale and Design of the Aldose Reductase Inhibition for Stabilization of Exercise Capacity in Heart Failure Trial (ARISE-HF) in Patients with High-Risk Diabetic Cardiomyopathy.
    Am Heart J. 2022 Nov 10. pii: S0002-8703(22)00287.
    PubMed     Abstract available


  35. SAVITZ ST, Leong T, Sung SH, Kitzman DW, et al
    Predicting Short-term Outcomes After Transcatheter Aortic Valve Replacement for Aortic Stenosis.
    Am Heart J. 2022 Nov 10. pii: S0002-8703(22)00286.
    PubMed     Abstract available


    October 2022
  36. KALWANI NM, Calma J, Varghese GM, Gupta A, et al
    The Patient-Reported Outcome Measurement in Heart Failure Clinic Trial: Rationale and Methods of The PRO-HF Trial.
    Am Heart J. 2022 Oct 26. pii: S0002-8703(22)00276.
    PubMed     Abstract available


    September 2022
  37. DESAI RJ, Glynn RJ, Everett BM, Schneeweiss S, et al
    Comparative effectiveness of empagliflozin in reducing the burden of recurrent cardiovascular hospitalizations among older adults with diabetes in routine clinical care.
    Am Heart J. 2022 Sep 20. pii: S0002-8703(22)00193.
    PubMed     Abstract available


  38. KAPUR NK, Kim RJ, Moses JW, Stone GW, et al
    Primary Left Ventricular Unloading with Delayed Reperfusion in Patients with Anterior ST-Elevation Myocardial Infarction: Rationale and Design of the STEMI-DTU Randomized Pivotal Trial.
    Am Heart J. 2022 Sep 1. pii: S0002-8703(22)00184.
    PubMed     Abstract available


    August 2022
  39. MURRAY EM, Greene SJ, Rao VN, Sun JL, et al
    Machine Learning to Define Phenotypes and Outcomes of Patients Hospitalized for Heart Failure with Preserved Ejection Fraction: Findings from ASCEND-HF.
    Am Heart J. 2022 Aug 22. pii: S0002-8703(22)00171.
    PubMed     Abstract available


  40. PERRY AS, Li S
    Association of Change in QRS Duration with Chronic Heart Failure Outcomes.
    Am Heart J. 2022 Aug 21. pii: S0002-8703(22)00167.
    PubMed     Abstract available


  41. PARLOW S, Di Santo P, Jung RG, Fam N, et al
    Transcatheter Mitral Valve Repair for Inotrope Dependent Cardiogenic Shock - Design and Rationale of the CAPITAL MINOS Trial.
    Am Heart J. 2022 Aug 21. pii: S0002-8703(22)00169.
    PubMed     Abstract available


    July 2022
  42. SUZUKI Y, Kaneko H, Yano Y, Okada A, et al
    Glycemic status and the association of change in blood pressure with incident cardiovascular disease.
    Am Heart J. 2022 Jul 21. pii: S0002-8703(22)00148.
    PubMed     Abstract available


    June 2022
  43. HILL JA
    Ambulatory inotropic therapy: To what end?
    Am Heart J. 2022;248:170-171.
    PubMed    


    May 2022
  44. PIERCE JB, Mentz RJ, Sun JL, Alhanti B, et al
    Titration of medical therapy and clinical outcomes among patients with heart failure with reduced ejection fraction: findings from the HF-ACTION trial.
    Am Heart J. 2022 May 28. pii: S0002-8703(22)00111.
    PubMed     Abstract available


  45. GREENE SJ, Lautsch D, Gaggin HK, Djatche LM, et al
    Contemporary Outpatient Management of Patients with Worsening Heart Failure with Reduced Ejection Fraction: Rationale and Design of the CHART-HF Study.
    Am Heart J. 2022 May 28. pii: S0002-8703(22)00110.
    PubMed     Abstract available


  46. HARRINGTON J, Udell JA, Jones WS, Anker SD, et al
    Empagliflozin in Patients Post Myocardial Infarction Rationale and Design of the EMPACT-MI Trial.
    Am Heart J. 2022 May 17. pii: S0002-8703(22)00095.
    PubMed     Abstract available


  47. AULIN J, Hijazi Z, Lindback J, Alexander JH, et al
    Biomarkers and heart failure events in patients with atrial fibrillation in the ARISTOTLE trial evaluated by a multistate model.
    Am Heart J. 2022 May 12. pii: S0002-8703(22)00091.
    PubMed     Abstract available


  48. LOPEZ-GALVEZ R, Marin F, Rivera-Caravaca JM
    Predicting heart failure in atrial fibrillation patients: What about using biomarkers?
    Am Heart J. 2022 May 7. pii: S0002-8703(22)00092.
    PubMed    


  49. GILSTRAP L, Zipkin RJ, Barnes JA, King A, et al
    Sacubitril/Valsartan vs. ACEi/ARB at Hospital Discharge and 5-Year Survival in Older Patients with Heart Failure with Reduced Ejection Fraction: A Decision Analysis Approach.
    Am Heart J. 2022 May 4. pii: S0002-8703(22)00082.
    PubMed     Abstract available


  50. JENSEN J, Omar M, Ali M, Frederiksen PH, et al
    The Effect of Empagliflozin on Contractile Reserve in Heart Failure: Prespecified Sub-Study of a Randomized, Double-Blind, and Placebo-Controlled Trial.
    Am Heart J. 2022 May 2. pii: S0002-8703(22)00083.
    PubMed     Abstract available


  51. SHARMA A, Elharram M, Afilalo J, Flannery A, et al
    A randomized controlled trial of renin-angiotensin-aldosterone system inhibitor management in patients admitted in hospital with COVID-19.
    Am Heart J. 2022;247:76-89.
    PubMed     Abstract available


    April 2022
  52. VON LEWINSKI D, Tripolt NJ, Sourij H, Pferschy PN, et al
    Ertugliflozin to reduce arrhythmic burden in ICD/CRT patients (ERASe-trial) - A phase III study.
    Am Heart J. 2022;246:152-160.
    PubMed     Abstract available


    March 2022
  53. FITZPATRICK JK, Ambrosy AP, Parikh RV, Tan TC, et al
    Prognostic Value of Echocardiography for Heart Failure and Death in Adults with Chronic Kidney Disease.
    Am Heart J. 2022 Mar 9. pii: S0002-8703(22)00027.
    PubMed     Abstract available


  54. ISRAR MZ, Zhan H, Salzano A, Voors AA, et al
    Surrogate markers of gut dysfunction are related to heart failure severity and outcome - from the BIOSTAT-CHF consortium.
    Am Heart J. 2022 Mar 9. pii: S0002-8703(22)00050.
    PubMed     Abstract available


  55. WYATT LH, Weaver AM, Moyer J, Schwartz JD, et al
    Short-term PM2.5 exposure and early-readmission risk: a retrospective cohort study in North Carolina heart failure patients.
    Am Heart J. 2022 Mar 6. pii: S0002-8703(22)00048.
    PubMed     Abstract available


    February 2022
  56. HASSAN R, Riehl-Tonn V, Dumanski SM, Lyons KJ, et al
    Female Sex-Specific Cardiovascular Risk Factors and Heart Failure Practice Guidelines.
    Am Heart J. 2022 Feb 4. pii: S0002-8703(22)00008.
    PubMed     Abstract available


    January 2022
  57. LEE DS, Straus SE, Austin PC, Mohamed S, et al
    Corrigendum to 'Rationale and design of the comparison of outcomes and access to care for heart failure (COACH) trial: a stepped wedge cluster randomized trial' American Heart Journal 2021; 240:1-10.
    Am Heart J. 2022 Jan 20. pii: S0002-8703(21)00465.
    PubMed    


    December 2021
  58. PATEL SV, Keshvani N, Pandey A, Vaduganathan M, et al
    Association of Readmission Penalty Amount with Subsequent 30-Day Risk Standardized Readmission and Mortality Rates Among Patients Hospitalized with Heart Failure: An Analysis of Get With The Guidelines - Heart Failure Participating Centers.
    Am Heart J. 2021 Dec 29. pii: S0002-8703(21)00494.
    PubMed     Abstract available


  59. HIGGINS AY, Annapureddy AR, Wang Y, Minges KE, et al
    Risk and Predictors of Mortality After Implantable Cardioverter-Defibrillator Implantation in Patients with Sarcoid Cardiomyopathy.
    Am Heart J. 2021 Dec 27. pii: S0002-8703(21)00491.
    PubMed     Abstract available


  60. CARNICELLI AP, Clare RM, Hofmann P, Chiswell K, et al
    Clinical Trajectory of Patients with a Worsening Heart Failure Event and Reduced Ventricular Ejection Fraction.
    Am Heart J. 2021 Dec 18. pii: S0002-8703(21)00476.
    PubMed     Abstract available


  61. KITAI T, Nemet I, Engelman T, Morales R, et al
    Intestinal Barrier Dysfunction is Associated with Elevated Right Atrial Pressure in Patients with Advanced Decompensated Heart Failure.
    Am Heart J. 2021 Dec 17. pii: S0002-8703(21)00466.
    PubMed     Abstract available


  62. PASALA S, Cooper LB, Psotka MA, Sinha SS, et al
    The Influence of Heart Failure on Clinical and Economic Outcomes among Older Adult >/=75 Years of Age with Acute Myocardial Infarction.
    Am Heart J. 2021 Dec 16. pii: S0002-8703(21)00474.
    PubMed     Abstract available


    November 2021
  63. BREATHETT KK, Xu H, Sweitzer NK, Calhoun E, et al
    Is the Affordable Care Act Medicaid Expansion Associated with Receipt of Heart Failure Guideline-Directed Medical Therapy By Race and Ethnicity?
    Am Heart J. 2021 Nov 20. pii: S0002-8703(21)00462.
    PubMed     Abstract available


  64. GHAZI L, Desai NR, Simonov M, Yamamoto Y, et al
    Rationale and Design of a Cluster-Randomized Pragmatic Trial Aimed at Improving Use of Guideline Directed Medical Therapy in Outpatients with Heart Failure: PRagmatic Trial Of Messaging to Providers about Treatment of Heart Failure (PROMPT-HF).
    Am Heart J. 2021 Nov 19. pii: S0002-8703(21)00461.
    PubMed     Abstract available


  65. ECHOUFFO-TCHEUGUI JB, Mwasongwe SE, Musani SK, Hall ME, et al
    Dysglycemia and Incident Heart Failure among Blacks: The Jackson Heart Study.
    Am Heart J. 2021 Nov 19. pii: S0002-8703(21)00446.
    PubMed     Abstract available


  66. KOSHY AN, Dinh DT, Fulcher J, Brennan AL, et al
    Long-Term Mortality in Asymptomatic Patients with Stable Ischemic Heart Disease undergoing Percutaneous Coronary Intervention.
    Am Heart J. 2021 Nov 12. pii: S0002-8703(21)00449.
    PubMed     Abstract available


  67. FENDRICK AM, Djatche L, Pulungan Z, Teigland C, et al
    Out-Of-Pocket Payments for Part D Covered Medications by Medicare Fee-For-Service Beneficiaries with Heart Failure with Reduced Ejection Fraction.
    Am Heart J. 2021 Nov 10. pii: S0002-8703(21)00443.
    PubMed     Abstract available


    October 2021
  68. ARITA VA, Santema BT, De With RR, Nguyen BO, et al
    Atrial function in paroxysmal AF patients with and without heart failure with preserved ejection fraction: data from the AF-RISK study.
    Am Heart J. 2021 Oct 21. pii: S0002-8703(21)00435.
    PubMed     Abstract available


  69. RASMUSSEN PV, Blanche P, Dalgaard F, Gislason GH, et al
    Electrical cardioversion of atrial fibrillation and the risk of brady-arrhythmic events: Rasmussen et al: Electrical cardioversion and bradycardia.
    Am Heart J. 2021 Oct 16. pii: S0002-8703(21)00434.
    PubMed     Abstract available


  70. EDWARDS JJ, Edelson JB, Katcoff H, Mondal A, et al
    Mental health disorders and emergency resource use and outcomes in ventricular assist device supported patients.
    Am Heart J. 2021;240:11-15.
    PubMed     Abstract available


  71. COTTER G, Davison BA, Edwards C, Senger S, et al
    Regional variation of effects of new antidiabetic medications in cardiovascular outcome trials.
    Am Heart J. 2021;240:73-80.
    PubMed     Abstract available


    September 2021
  72. SALAH HM, Khan Minhas AM, Khan MS, Khan SU, et al
    Trends in Hospitalizations for Heart Failure, Acute Myocardial Infarction, and Stroke in the United States from 2004-2018.
    Am Heart J. 2021 Sep 25. pii: S0002-8703(21)00238.
    PubMed     Abstract available


  73. TROMP J, Ouwerkerk W, Cleland JGF, Chandramouli C, et al
    A Global Perspective of Racial Differences and Outcomes in Patients Presenting with Acute Heart Failure.
    Am Heart J. 2021 Sep 10. pii: S0002-8703(21)00228.
    PubMed     Abstract available


  74. CAVENDER MA, O'Donoghue M, Abbate A, Aylward P, et al
    Inhibition of p38 MAP Kinase in Patients with ST-Elevation Myocardial Infarction - Findings from the LATITUDE TIMI 60 Trial.
    Am Heart J. 2021 Sep 8. pii: S0002-8703(21)00229.
    PubMed     Abstract available


    August 2021
  75. BILCHICK KC, Stafford P, Laja O, Elumogo C, et al
    Relationship of Ejection Fraction and Natriuretic Peptide Trajectories in Heart Failure with Baseline Reduced and Mid-Range Ejection Fraction.
    Am Heart J. 2021 Aug 25. pii: S0002-8703(21)00220.
    PubMed     Abstract available


    July 2021
  76. MOGHADDAM N, Malhi N, Toma M
    Impact of Oral Soluble Guanylate Cyclase Stimulators in Heart Failure: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.
    Am Heart J. 2021 Jul 17. pii: S0002-8703(21)00182.
    PubMed     Abstract available


  77. CHRISTENSEN DM, Butt JH, Fosbol E, Kober L, et al
    Admission Rates During a Second COVID-19 Lockdown.
    Am Heart J. 2021 Jul 15. pii: S0002-8703(21)00180.
    PubMed     Abstract available


  78. NUNEZ-GIL IJ, Olier I, Feltes G, Viana-Llamas MC, et al
    Renin-angiotensin system inhibitors effect before and during hospitalization in COVID-19 outcomes: Final analysis of the international HOPE COVID-19 (Health Outcome Predictive Evaluation for COVID-19) registry.
    Am Heart J. 2021;237:104-115.
    PubMed     Abstract available


    June 2021
  79. SZUMMER K, Perino AC, Fan J, Kothari M, et al
    Association of kidney function and atrial fibrillation progression to clinical outcomes in patients with cardiac implantable electronic devices.
    Am Heart J. 2021 Jun 9. pii: S0002-8703(21)00149.
    PubMed     Abstract available


  80. JENSEN J, Omar M, Moller JE, Schou M, et al
    Response to Patoulias et al. letter regarding article "Twelve weeks of treatment with empagliflozin in patients with heart failure and reduced ejection fraction: A double-blinded, randomized, and placebo-controlled trial".
    Am Heart J. 2021;236:106.
    PubMed    


  81. PATOULIAS D, Papadopoulos C, Doumas M
    Sodium-glucose co-transporter-2 inhibitors and sacubitril/valsartan combination in patients with heart failure with reduced ejection fraction; does it deserve our attention?
    Am Heart J. 2021;236:104-105.
    PubMed    


    May 2021
  82. FUDIM M, Spates T, Sun JL, Kittipibul V, et al
    Early Diuretic Strategies and the Association With In-Hospital and Post-Discharge Outcomes in Acute Heart Failure.
    Am Heart J. 2021 May 27. pii: S0002-8703(21)00140.
    PubMed     Abstract available


  83. KITTIPIBUL V, Blumer V, Hernandez GA, Fudim M, et al
    Pre-operative Atrial Fibrillation and Early Right Ventricular Failure after Left Ventricular Assist Device Implantation: A Systematic Review and Meta-Analysis.
    Am Heart J. 2021 May 23. pii: S0002-8703(21)00138.
    PubMed     Abstract available


  84. RODRIGUES DOS SANTOS M, Alves MNN, Jordao CP, Pinto CEN, et al
    Sacubitril/Valsartan Versus Enalapril on Exercise Capacity in Patients with Heart Failure with Reduced Ejection Fraction: A Randomized, Double-Blind, Active-Controlled Study: Sacubitril/Valsartan and Enalapril on Peak VO2 in Patients with Heart Failur
    Am Heart J. 2021 May 13. pii: S0002-8703(21)00125.
    PubMed     Abstract available


  85. CHEN Y, Lawrence J, Stockbridge N
    Days Alive Out of Hospital in Heart Failure: Insights from the PARADIGM-HF and CHARM Trials.
    Am Heart J. 2021 May 10. pii: S0002-8703(21)00119.
    PubMed     Abstract available


  86. GRUBB CS, Truby LK, Topkara VK, Bohnen MS, et al
    Advanced Heart Failure Patients Supported with Ambulatory Inotropic Therapy: What Defines Success of Therapy?
    Am Heart J. 2021 May 10. pii: S0002-8703(21)00121.
    PubMed     Abstract available


  87. LEE DS, Straus SE, Austin PC, Mohamed S, et al
    Rationale and Design of the Comparison of Outcomes and Access to Care for Heart Failure (COACH) Trial: A Stepped Wedge Cluster Randomized Trial.
    Am Heart J. 2021 May 10. pii: S0002-8703(21)00123.
    PubMed     Abstract available


  88. SHI X, He J, Lin M, Liu C, et al
    Comparative effectiveness of team-based care with a clinical decision support system versus team-based care alone on cardiovascular risk reduction among patients with diabetes: Rationale and design of the D4C trial.
    Am Heart J. 2021 May 3. pii: S0002-8703(21)00111.
    PubMed     Abstract available


  89. SINGH JP, Walsh MN, Kubo SH, Auricchio A, et al
    Modified design of stimulation of the left ventricular endocardium for cardiac resynchronization therapy in nonresponders, previously untreatable and high-risk upgrade patients (SOLVE-CRT) trial.
    Am Heart J. 2021;235:158-162.
    PubMed     Abstract available


  90. AHMED I, Merchant FM, Curtis JP, Parzynski CS, et al
    Impact of insurance status on ICD implantation practice patterns: Insights from the NCDR ICD registry.
    Am Heart J. 2021;235:44-53.
    PubMed     Abstract available


    April 2021
  91. MEHMOOD M
    Letter to the Editor by Mehmood regarding the article "Outcomes and Cost Among Medicare Beneficiaries Hospitalized for Heart Failure Assigned to Accountable Care Organizations".
    Am Heart J. 2021;234:132.
    PubMed    


    March 2021
  92. ALFREDSSON J, James SK, Erlinge D, Herlitz J, et al
    Randomized comparison of early supplemental oxygen versus ambient air in patients with confirmed myocardial infarction: Sex related outcomes from DETO2X-AMI.
    Am Heart J. 2021 Mar 6. pii: S0002-8703(21)00066.
    PubMed     Abstract available


  93. BROOKSBANK JA, Greene SJ, Harris HM, Stebbins A, et al
    Beta-blocker and ACE-inhibitor dosing as a function of body surface area: From the HF-ACTION trial.
    Am Heart J. 2021;233:1-4.
    PubMed     Abstract available


    February 2021
  94. SHAHZEB KHAN M, Kristensen SL, Vaduganathan M, Kober L, et al
    Natriuretic Peptide Plasma Concentrations and Risk of Cardiovascular Versus Non-Cardiovascular Events in Heart Failure with Reduced Ejection Fraction Insights from the PARADIGM-HF and ATMOSPHERE Trials.
    Am Heart J. 2021 Feb 20. pii: S0002-8703(21)00054.
    PubMed     Abstract available


  95. RO O, Qr Y, A E, P A, et al
    Cardiac transplantation outcomes in patients with amyloid cardiomyopathy.
    Am Heart J. 2021 Feb 20. pii: S0002-8703(21)00055.
    PubMed     Abstract available


  96. JENTZER JC, Ahmed AM, Vallabhajosyula S, Burstein B, et al
    Shock in the cardiac intensive care unit: Changes in epidemiology and prognosis over time.
    Am Heart J. 2021;232:94-104.
    PubMed     Abstract available


    January 2021
  97. ALBERT NM, Tyson RJ, Hill CL, DeVore AD, et al
    Variation in use and dosing escalation of renin angiotensin system, mineralocorticoid receptor antagonist, angiotensin receptor neprilysin inhibitor and beta-blocker therapies in heart failure and reduced ejection fraction: Association of comorbiditie
    Am Heart J. 2021 Jan 23. pii: S0002-8703(21)00028.
    PubMed     Abstract available


  98. R P, G W, J R, M T, et al
    A Randomized Ablation-based atrial Fibrillation rhythm control versus rate control Trial in patients with heart failure and high burden Atrial Fibrillation.
    Am Heart J. 2021 Jan 17. pii: S0002-8703(21)00016.
    PubMed     Abstract available


  99. ZHAO Y, Sivaswamy A, Lee MK, Izadnegahdar M, et al
    A Feasibility Study for CODE-MI: High-Sensitivity Cardiac Troponin - Optimizing the Diagnosis of Acute Myocardial Infarction/Injury in Women.
    Am Heart J. 2021 Jan 15. pii: S0002-8703(21)00012.
    PubMed     Abstract available


  100. ISRAR MZ, Bernieh D, Salzano A, Cassambai S, et al
    Association of gut-related metabolites with outcome in acute heart failure.
    Am Heart J. 2021 Jan 14. pii: S0002-8703(21)00010.
    PubMed     Abstract available


  101. ADACHI Y, Yamamoto M, Shimura T, Yamaguchi R, et al
    Late kidney injury after transcatheter aortic valve replacement.
    Am Heart J. 2021 Jan 14. pii: S0002-8703(21)00011.
    PubMed     Abstract available


  102. YERASI C, Tripathi B, Wang Y, Forrestal BJ, et al
    National trends and 30-day readmission rates for next-day-discharge transcatheter aortic valve replacement: An analysis from the Nationwide Readmissions Database, 2012-2016.
    Am Heart J. 2021;231:25-31.
    PubMed     Abstract available


    December 2020
  103. MALIK AO, Amin A, Kennedy K, Qintar M, et al
    Patient-centered contrast thresholds to reduce acute kidney injury in high-risk patients undergoing percutaneous coronary intervention.
    Am Heart J. 2020 Dec 23. pii: S0002-8703(20)30415.
    PubMed     Abstract available


  104. SARRAJU A, Li J, Cannon CP, Chang TI, et al
    Effects of Canagliflozin on Cardiovascular, Renal, and Safety Outcomes in Participants With Type 2 Diabetes and Chronic Kidney Disease According to History of Heart Failure: Results From the CREDENCE Trial.
    Am Heart J. 2020 Dec 20. pii: S0002-8703(20)30407.
    PubMed     Abstract available


  105. VAISHNAV J, Hubbard A, Chasler JE, Lepley D, et al
    Management of Heart Failure in Cardiac Amyloidosis Using an Ambulatory Diuresis Clinic.
    Am Heart J. 2020 Dec 19. pii: S0002-8703(20)30411.
    PubMed     Abstract available


  106. NUCCIA M, Claudia M, Alice S, Guido T, et al
    Early intra-aortic balloon pump in acute decompensated heart failure complicated by cardiogenic shock: rationale and design of the randomized Altshock- 2 trial.
    Am Heart J. 2020 Dec 15. pii: S0002-8703(20)30399.
    PubMed     Abstract available


    November 2020
  107. HAMO CE, Fonarow GC, Greene SJ, Vaduganathan M, et al
    Temporal Trends in Risk Profiles Among Patients Hospitalized for Heart Failure.
    Am Heart J. 2020 Nov 29. pii: S0002-8703(20)30397.
    PubMed     Abstract available


  108. RASLAN IR, Ross HJ, Fowler RA, Scales DC, et al
    The Associations Between Direct and Delayed Critical Care Unit Admission with Mortality and Readmissions Among Patients with Heart Failure.
    Am Heart J. 2020 Nov 6. pii: S0002-8703(20)30369.
    PubMed     Abstract available


    October 2020
  109. COX ZL, Collins SP, Aaron M, Hernandez GA, et al
    Efficacy and Safety of Dapagliflozin in Acute Heart Failure: Rationale and Design of the DICTATE-AHF trial.
    Am Heart J. 2020 Oct 31. pii: S0002-8703(20)30357.
    PubMed     Abstract available


  110. BOAS R, Thune JJ, Pehrson S, Kober L, et al
    Atrial fibrillation is a marker of increased mortality risk in non-ischemic heart failure - results from the DANISH Trial.
    Am Heart J. 2020 Oct 31. pii: S0002-8703(20)30359.
    PubMed     Abstract available


  111. NORDENSKJOLD AM, Agewall S, Atar D, Baron T, et al
    Randomized evaluation of beta blocker and ACE-inhibitor/angiotensin receptor blocker treatment in patients with myocardial infarction with non-obstructive coronary arteries (MINOCA-BAT): Rationale and design.
    Am Heart J. 2020;231:96-104.
    PubMed     Abstract available


  112. SALAH HM, Al'Aref SJ, Khan MS, Al-Hawwas M, et al
    Effect of sodium-glucose cotransporter 2 inhibitors on cardiovascular and kidney outcomes-Systematic review and meta-analysis of randomized placebo-controlled trials.
    Am Heart J. 2020;232:10-22.
    PubMed     Abstract available


  113. FRIEDMAN DJ, Emerek K, Kisslo J, Sogaard P, et al
    Left bundle branch block is associated with a similar Dyssynchronous phenotype in heart failure patients with Normal and reduced ejection fractions.
    Am Heart J. 2020 Oct 21. pii: S0002-8703(20)30338.
    PubMed     Abstract available


  114. WIGGERS H, Kober L, Gislason G, Schou M, et al
    The DANish randomized, double-blind, placebo controlled trial in patients with chronic HEART failure (DANHEART): A 2 x 2 factorial trial of hydralazine-isosorbide dinitrate in patients with chronic heart failure (H-HeFT) and metformin in patients with
    Am Heart J. 2020 Oct 8. pii: S0002-8703(20)30276.
    PubMed     Abstract available


    September 2020
  115. BLUMER V, Greene SJ, Ortiz M, Kittipibul V, et al
    In-hospital outcomes after bariatric surgery in patients with heart failure.
    Am Heart J. 2020 Sep 26. pii: S0002-8703(20)30260.
    PubMed     Abstract available


  116. MENTZ RJ, Xu H, O'Brien EC, Thomas L, et al
    PROVIDE-HF primary results: Patient-reported outcomes inVestigation following initiation of drug therapy with Entresto (Sacubitril/valsartan) in heart failure.
    Am Heart J. 2020 Sep 24. pii: S0002-8703(20)30265.
    PubMed     Abstract available


  117. GRUBB AF, Pumill CA, Greene SJ, Wu A, et al
    Tobacco smoking in patients with heart failure and coronary artery disease: A 20-year experience at Duke University medical center.
    Am Heart J. 2020 Sep 24. pii: S0002-8703(20)30264.
    PubMed     Abstract available


  118. SHAIKH A, Ochani RK, Khan MS, Riaz H, et al
    Contribution of individual components to composite endpoints in contemporary cardiovascular randomized controlled trials.
    Am Heart J. 2020 Sep 14. pii: S0002-8703(20)30254.
    PubMed     Abstract available


    August 2020
  119. HONIGBERG MC, Pirruccello JP, Aragam K, Sarma AA, et al
    Menopausal Age and Left Ventricular Remodeling by Cardiac Magnetic Resonance Imaging Among 14,550 Women.
    Am Heart J. 2020 Aug 19. pii: S0002-8703(20)30235.
    PubMed     Abstract available


  120. BERRY N, Mauri L, Feldman T, Komtebedde J, et al
    Transcatheter InterAtrial Shunt Device for the treatment of heart failure: Rationale and design of the pivotal randomized trial to REDUCE Elevated Left Atrial Pressure in Patients with Heart Failure II (REDUCE LAP-HF II).
    Am Heart J. 2020;226:222-231.
    PubMed     Abstract available


    July 2020
  121. BHARDWAJ B, Cohen DJ, Vemulapalli S, Kosinski AS, et al
    Outcomes of transcatheter aortic valve replacement for patients with severe aortic stenosis and concomitant aortic insufficiency: Insights from the TVT Registry.
    Am Heart J. 2020;228:57-64.
    PubMed     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Chronic Heart Failure is free of charge.